AEGLEA BIOTHERAPEUTICS INC (AGLE) Forecast, Price Target & Analyst Ratings

NASDAQ:AGLE • US00773J2024

Current stock price

12.01 USD
+0.97 (+8.79%)
At close:
11.88 USD
-0.13 (-1.08%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AEGLEA BIOTHERAPEUTICS INC (AGLE).

Forecast Snapshot

Consensus Price Target

Price Target
$17.85
+ 48.63% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Mar 4, 2024
Period
Q4 / 2023
EPS Estimate
-$0.93
Revenue Estimate
374.003K
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.22%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$17.85
Upside
+ 48.63%
From current price of $12.01 to mean target of $17.85, Based on 9 analyst forecasts
Low
$12.12
Median
$17.85
High
$24.15

Price Target Revisions

1 Month
-1.41%
3 Months
2,400.00%

Price Target Summary

9 Wall Street analysts provided a forecast for the next 12 months for AGLE. The average price target is 17.85 USD. This implies a price increase of 48.63% is expected in the next year compared to the current price of 12.01.
The average price target has been revised upward by 2400% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

AGLE Current Analyst RatingAGLE Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

AGLE Historical Analyst RatingsAGLE Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
82.22%
AGLE was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about AGLE.
In the previous month the buy percentage consensus was at a similar level.
AGLE was analyzed by 9 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2023-08-16Wells FargoMaintains Equal-Weight -> Equal-Weight
2023-07-25StifelInitiate Buy
2023-04-12LifeSci CapitalDowngrade Outperform -> Market Perform
2023-04-12JonesTradingDowngrade Buy -> Hold
2023-03-03HC Wainwright & Co.Maintains Neutral
2022-10-28Wells FargoUpgrade Equal-Weight -> Overweight
2022-08-09Wells FargoMaintains Equal-Weight
2022-06-03NeedhamDowngrade Buy -> Hold
2022-06-03HC Wainwright & Co.Downgrade Buy -> Neutral
2022-05-23Piper SandlerMaintains Overweight
2022-05-06NeedhamMaintains Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Mar 4, 2024
Period
Q4 / 2023
EPS Estimate
-$0.93
Revenue Estimate
374.003K
Revenue Q2Q
120.00%
EPS Q2Q
79.37%
Number of Analysts
5

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
65.46%
EPS (3 Months)
-766.67%

Next Earnings Summary

AGLE is expected to report earnings on 3/4/2024. The consensus EPS estimate for the next earnings is -0.93 USD and the consensus revenue estimate is 374.00K USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2023 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
AGLE revenue by date.AGLE revenue by date.
18.74M2.33M
-87.57%		1.292M
-44.55%		13.6M
952.63%
-100.00%		71.4M
EBITDA
YoY % growth
AGLE ebitda by date.AGLE ebitda by date.
-80.48M
-0.71%		-64.07M
20.39%		-83.21M
-29.87%		-97.92M
-17.68%		N/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
AGLE ebit by date.AGLE ebit by date.
-81.48M
-1.43%		-65.65M
19.43%		-84.78M
-29.14%		-224.502M
-164.81%		-73.95M
67.06%		-34.912M
52.79%		-255M
-630.41%		-306M
-20.00%		-357M
-16.67%		-408M
-14.29%		-479.4M
-17.50%
Operating Margin
AGLE operating margin by date.AGLE operating margin by date.
N/A-350.32%-3,638.63%-17,376.32%-543.75%N/AN/AN/AN/AN/A-671.43%
EPS
YoY % growth
AGLE eps by date.AGLE eps by date.
-1.61
34.29%		-8.44
-424.22%		-25.25
-199.17%		-5.43
78.51%		-2.36
56.52%		-3.98
-68.59%		-4.79
-20.51%		-5.56
-15.96%		-6.27
-12.84%		-6.94
-10.57%		-7.85
-13.24%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.93
79.37%		-0.68
86.43%		-0.49
98.82%		-0.74
92.03%		-0.53
42.86%
Revenue
Q2Q % growth		374.003K
120.00%
-100.00%		10.2M
1,378.26%		10.2M
2,627.25%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-35.224M
-83.84%		-29.835M
-58.61%		-20.91M
85.99%		-33.66M
-1.26%		-25.245M
28.33%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

AGLE Yearly Revenue VS EstimatesAGLE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 2030 20M 40M 60M
AGLE Yearly EPS VS EstimatesAGLE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -20 -40 -60

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
22.59%
EPS Next 5 Year
12.22%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
-14.87%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

AEGLEA BIOTHERAPEUTICS INC / AGLE Forecast FAQ

What do analysts expect the price target to be for AEGLEA BIOTHERAPEUTICS INC (AGLE)?

9 analysts have analysed AGLE and the average price target is 17.85 USD. This implies a price increase of 48.63% is expected in the next year compared to the current price of 12.01.

Can you provide the upcoming earnings date for AEGLEA BIOTHERAPEUTICS INC?

AEGLEA BIOTHERAPEUTICS INC (AGLE) will report earnings on 2024-03-04, after the market close.

What are the consensus estimates for AGLE stock next earnings?

The consensus EPS estimate for the next earnings of AEGLEA BIOTHERAPEUTICS INC (AGLE) is -0.93 USD and the consensus revenue estimate is 374.00K USD.

What is the consensus rating for AEGLEA BIOTHERAPEUTICS INC (AGLE) stock?

The consensus rating for AEGLEA BIOTHERAPEUTICS INC (AGLE) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.